Cross-Sectional HIV Incidence Surveillance: A Benchmarking of Approaches for Estimating the ‘Mean Duration of Recent Infection’

Abstract The application of biomarkers for ‘recent’ infection in cross-sectional HIV incidence surveillance requires the estimation of critical biomarker characteristics. Various approaches have been employed for using longitudinal data to estimate the Mean Duration of Recent Infection (MDRI) – the average time in the ‘recent’ state. In this systematic benchmarking of MDRI estimation approaches, a simulation platform was used to measure accuracy and precision of over twenty approaches, in thirty scenarios capturing various study designs, subject behaviors and test dynamics that may be encountered in practice. Results highlight that assuming a single continuous sojourn in the ‘recent’ state can produce substantial bias. Simple interpolation provides useful MDRI estimates provided subjects are tested at regular intervals. Regression performs the best – while ‘random effects’ describe the subject-clustering in the data, regression models without random effects proved easy to implement, stable, and of similar accuracy in scenarios considered; robustness to parametric assumptions was improved by regressing ‘recent’/‘non-recent’ classifications rather than continuous biomarker readings. All approaches were vulnerable to incorrect assumptions about subjects’ (unobserved) infection times. Results provided show the relationships between MDRI estimation performance and the number of subjects, inter-visit intervals, missed visits, loss to follow-up, and aspects of biomarker signal and noise.

[1]  R. Byers,et al.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence. , 2002, AIDS research and human retroviruses.

[2]  Tanmoy Bhattacharya,et al.  Modeling sequence evolution in acute HIV-1 infection. , 2009, Journal of theoretical biology.

[3]  Connie Celum,et al.  HIV incidence determination in the United States: a multiassay approach. , 2013, The Journal of infectious diseases.

[4]  L Meyer,et al.  Principles and uses of HIV incidence estimation from recent infection testing--a review. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[5]  B. Branson,et al.  Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay. , 2006, AIDS research and human retroviruses.

[6]  Stephen W Lagakos,et al.  Augmented Cross‐Sectional Prevalence Testing for Estimating HIV Incidence , 2010, Biometrics.

[7]  A. Burchell,et al.  Symptomatic primary HIV infection or risk experiences? Circumstances surrounding HIV testing and diagnosis among recent seroconverters , 2003, International journal of STD & AIDS.

[8]  B. Turnbull The Empirical Distribution Function with Arbitrarily Grouped, Censored, and Truncated Data , 1976 .

[9]  L Meyer,et al.  Estimation of the Distribution of Infection Times Using Longitudinal Serological Markers of HIV: Implications for the Estimation of HIV Incidence , 2011, Biometrics.

[10]  Till Bärnighausen,et al.  A New General Biomarker-based Incidence Estimator , 2012, Epidemiology.

[11]  Bernard Branson,et al.  Determination of mean recency period for estimation of HIV type 1 Incidence with the BED-capture EIA in persons infected with diverse subtypes. , 2011, AIDS research and human retroviruses.

[12]  R Brookmeyer,et al.  Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. , 1995, American journal of epidemiology.

[13]  Barbara Suligoi,et al.  Estimating the distribution of the window period for recent HIV infections: A comparison of statistical methods , 2010, Statistics in medicine.

[14]  Ekkehard Kopp,et al.  Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay , 2008, AIDS.

[15]  John N. Nkengasong,et al.  Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies , 2012, PloS one.

[16]  S. Owen,et al.  Evaluation of a Multiplex Assay for Estimation of HIV-1 Incidence , 2013, PloS one.

[17]  Till Bärnighausen,et al.  Errors in ‘BED’-Derived Estimates of HIV Incidence Will Vary by Place, Time and Age , 2009, PloS one.

[18]  David Wright,et al.  HIV seroconverting donors delay their return: screening test implications , 2002, Transfusion.

[19]  Oliver Laeyendecker,et al.  Estimation of HIV incidence using multiple biomarkers. , 2013, American journal of epidemiology.

[20]  Bertran Auvert,et al.  Mixture models for calibrating the BED for HIV incidence testing. , 2014, Statistics in medicine.

[21]  Debra Hanson,et al.  Lower-Sensitivity and Avidity Modifications of the Vitros Anti-HIV 1+2 Assay for Detection of Recent HIV Infections and Incidence Estimation , 2012, Journal of Clinical Microbiology.

[22]  Joseph Vyankandondera,et al.  Dual Testing Algorithm of BED-CEIA and AxSYM Avidity Index Assays Performs Best in Identifying Recent HIV Infection in a Sample of Rwandan Sex Workers , 2011, PloS one.

[23]  Alex Welte,et al.  Workshop summary: Novel biomarkers for HIV incidence assay development. , 2012, AIDS research and human retroviruses.

[24]  G A Satten,et al.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. , 1998, JAMA.

[25]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[26]  John Hargrove,et al.  How Should We Best Estimate the Mean Recency Duration for the BED Method? , 2012, PloS one.

[27]  Gonzalo Domingo,et al.  More and Better Information to Tackle HIV Epidemics: Towards Improved HIV Incidence Assays , 2011, PLoS medicine.

[28]  Oliver Laeyendecker,et al.  Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay , 2014, AIDS.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  Alex Welte,et al.  Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. , 2010, AIDS.

[31]  Reshma Kassanjee,et al.  Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository , 2014, AIDS.

[32]  J. Parry,et al.  Assays for the detection of recent infections with human immunodeficiency virus type 1. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[33]  Oliver Laeyendecker,et al.  Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward. , 2010, Journal of HIV AIDS surveillance & epidemiology.

[34]  Reshma Kassanjee,et al.  Recalibration of the Limiting Antigen Avidity EIA to Determine Mean Duration of Recent Infection in Divergent HIV-1 Subtypes , 2015, PloS one.